EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Revolution Medicines EBITDA Margin % Related Terms
Revolution Medicines EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Revolution Medicines's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:42Z vs ONC, ALNY, RPRX: EBITDA Margin % Comparison
For the Biotechnology subindustry, Revolution Medicines's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Revolution Medicines EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Revolution Medicines's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Revolution Medicines's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Revolution Medicines (FRA:42Z) has a EBITDA Margin % of 0.00% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Revolution Medicines and its competitors. According to the industry distribution chart, Revolution Medicines ranks #999999 out of 944 companies in the Biotechnology industry.
Is Revolution Medicines' EBITDA Margin % too high?
Revolution Medicines' current EBITDA Margin % is 0.00%. Based on the distribution chart, Revolution Medicines ranks #999999 out of 944 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Revolution Medicines has a GF Score™ of 30/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Revolution Medicines' EBITDA Margin % compare to ONC and ALNY?
According to the Biotechnology industry distribution chart, Revolution Medicines ranks #999999 out of 944 companies for EBITDA Margin %. This places Revolution Medicines in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Revolution Medicines and its competitors. Revolution Medicines's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Revolution Medicines stock overvalued right now?
Based on GuruFocus' analysis, Revolution Medicines (FRA:42Z) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.39, compared to a current price of €159.50 — trading 40797.4% above its estimated fair value. The current EBITDA Margin % is 0.00%. Revolution Medicines' overall GF Score™ is 30/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Revolution Medicines (FRA:42Z), the current EBITDA Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Revolution Medicines (FRA:42Z) Overvalued in 2026?
Based on GuruFocus' analysis, Revolution Medicines stock appears to be overvalued.
The current stock price of €159.50 is trading 40797.4% above its estimated GF Value™ of €0.39.
GuruFocus considers Revolution Medicines to be Significantly Overvalued.
Key valuation signals for FRA:42Z:
EBITDA Margin %: 0.00%
GF Value™: €0.39 vs. price of €159.50 (40797.4% above fair value)
No single metric tells the full story. See the FRA:42Z stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Revolution Medicines Inc is a clinical-stage precision oncology company developing novel targeted therapies for RAS-addicted cancers. The Company possesses structure-based drug discovery capabilities built upon chemical biology and cancer pharmacology know-how and proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites. Its research and development pipeline comprises inhibitors that bind directly to RAS variants (RAS(ON) Inhibitors), designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or other therapeutic agents.
30GF Score
Get the complete analysis for FRA:42Z
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:42Z has been successfully added to your 
